RTP Mobile Logo
Dissecting the Decision: Investigators Discuss Available and Emerging Data on the Use of PARP Inhibitors in Ovarian Cancer and Other Novel Systemic Strategies Under Development for Gynecologic Cancers
Released August 2017

Featuring interviews with Drs Jonathan A Ledermann and Bradley J Monk. (Audio Content)

CE Disclosures and Faculty Information

    Gynecologic cancers comprise 5 primary cancers affecting the ovaries, uterine corpus (endometrial cancer), uterine cervix (cervical cancer), vulva and vagina. Despite many commonalities, each of these diseases is quite distinct, and management algorithms employed for each are consequently varied. Ovarian cancer (OC) is the fifth most common cause of cancer mortality in women, causing more deaths than any other gynecologic cancer. Given the significant number of clinical and research questions created by recent advances in the management of OC, including the introduction of PARP inhibitors, clinicians must be aware of emerging data and available protocols so that they may effectively counsel their patients. To bridge the gap between research and patient care, this program will feature special highlights from 2 satellite CME symposia presented during the 2017 Society of Gynecologic Oncology meeting. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers with the formulation of up-to-date clinical management strategies for various gynecologic cancers.


    • Evaluate current and emerging treatment options for OC, and use this information to appropriately select and sequence systemic therapeutic approaches for patients with this disease.
    • Appraise the efficacy and safety of approved and investigational PARP inhibitors as monotherapy for patients with BRCA-mutant advanced OC, and employ this information in the formulation of protocol and clinical treatment recommendations for these individuals.
    • Appreciate the recent FDA approval of niraparib as maintenance therapy for patients with recurrent, platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer, and safely integrate this agent into routine clinical practice.
    • Consider the role of the anti-VEGF antibody bevacizumab in the initial and long-term treatment of advanced OC, cervical cancer and endometrial cancer.
    • Recognize the mechanisms of action, emerging efficacy data and toxicity profiles of investigational agents in gynecologic cancers to effectively prioritize clinical trial opportunities for appropriate patients.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form at ResearchToPractice.com/GynOnc17/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LedermannAdvisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Pfizer Inc. Dr MonkConsulting Agreements: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Genentech BioOncology, Gradalis Inc, INSYS Therapeutics Inc, Mateon Therapeutics, Merck, Pfizer Inc, PPD, Precision Oncology, Roche Laboratories Inc, Tesaro Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, Genentech BioOncology, Lilly, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Morphotek Inc, Tesaro Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImmunoGen Inc, Myriad Genetic Laboratories Inc and Tesaro Inc. 

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: August 2017
    Expiration date: August 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Dissecting the Decision: Investigators Discuss Available and Emerging Data on the Use of PARP Inhibitors in Ovarian Cancer and Other Novel Systemic Strategies Under Development for Gynecologic Cancers
Released August 2017

Featuring interviews with Drs Jonathan A Ledermann and Bradley J Monk. (Audio Content)

Read print: